What Instil Bio does

Instil Bio, Inc. is a clinical-stage biotechnology company headquartered in Dallas, Texas (5949 Sherry Lane, Suite 820) and listed on NASDAQ under ticker TIL. Founded in 2020, the company was historically focused on developing cell therapies for solid tumor cures, operating through its wholly-owned subsidiary Axion Bio. The original pipeline consisted of drug candidates AXN-2510 and AXN-27M, which were licensed ex-China from ImmuneOnco Biopharmaceuticals in August 2024 under a License and Collaboration Agreement.

As of early 2026, Instil Bio has undergone a near-complete strategic reset. In January 2026, Axion Bio discontinued clinical development of AXN-2510 and terminated its agreement with ImmuneOnco, with all ex-China rights reverting to ImmuneOnco and a 45.81% single-day stock decline. The company closed the majority of its Manchester, UK operations in March 2026 and replaced its auditor with RSM US LLP in April 2026. The company currently has no active therapeutic products or candidates in disclosed development.

The business model is pre-revenue: there are no commercial products, no licensing royalties currently flowing in (the prior ImmuneOnco agreement has been terminated), and the company reported a net loss of $71.4 million for full year 2025 and a $0.62 per share net loss in Q1 2026. Instil Bio is explicitly pivoting toward external innovation, with management stating in May 2026 that it is actively evaluating potential acquisitions and in-licensing opportunities to build a new pipeline. The company maintains a cash position of approximately $74.7 million as of Q1 2026, which management expects to fund operations beyond 2027, providing a finite runway for executing transactions before a capital raise or strategic alternative becomes necessary.

Name

Instil Bio

Legal name

Instil Bio, Inc.

Website

https://instilbio.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Instil Bio is a pre-revenue, clinical-stage biotechnology company that has discontinued its cell-therapy programs and is now pivoting toward external innovation, actively evaluating acquisitions and in-licensing opportunities to build a new pipeline using its $74.7M cash balance.

Ownership category

akta.pro rank

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pre-Revenue / Development Stage: Instil Bio is a clinical-stage biotechnology company with no commercial products generating revenue. The company reported a net loss of $71.4 million for full year 2025 and $0.62 per share loss in Q1 2026. The company is pivoting toward external innovation, evaluating potential acquisitions and in-licensing opportunities to build a focused pipeline.

Marketing channels3 records

Core offering

Instil Bio is a clinical-stage biotechnology company that has historically developed cell therapies for solid tumors through its subsidiary Axion Bio, including drug candidates AXN-2510 and AXN-27M. After discontinuing all disclosed clinical programs in January 2026 and terminating its license with ImmuneOnco Biopharmaceuticals, the company is now pivoting to evaluate potential acquisitions and in-licensing opportunities to build a focused therapeutic pipeline. The company currently has no active clinical candidates under disclosed development.

Product overview

Instil Bio is a biotechnology company focused on identifying and advancing innovative therapeutic opportunities. Based on recent corporate disclosures, the company has discontinued all of its disclosed clinical programs through its subsidiary Axion Bio, including AXN-2510 and AXN-27M, following the termination of its license and collaboration agreement with ImmuneOnco Biopharmaceuticals in January 2026. The company is currently pivoting toward external innovation, actively evaluating potential acquisitions and in-licensing opportunities to build a focused pipeline. Instil Bio maintains a cash position of approximately $74.7 million as of Q1 2026, expected to fund operations beyond 2027. No active therapeutic products or candidates are currently in disclosed development.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered former core, internal and minor.

• ImmuneOnco Biopharmaceuticalsformer coreStrategic or Co-development Partner · 1 January 2026License and Collaboration Agreement for drug candidates AXN-2510 and AXN-27M. The original agreement was signed in August 2024, granting Axion Bio rights to develop and commercialize these candidates outside of China. The agreement was terminated in January 2026, with all ex-China rights reverting to ImmuneOnco.
• Axion BiointernalOthers · 1 January 2026Wholly owned subsidiary of Instil Bio that discontinued clinical development of AXN-2510 and terminated the license agreement with ImmuneOnco in January 2026. Effectively ended all of the company's disclosed programs.
• RSM US LLPminorOthersAppointed as new auditor in April 2026, replacing Deloitte & Touche LLP for the fiscal year ending December 31, 2026. The SEC filing indicated no disagreements or adverse opinions from Deloitte.
• Deloitte & Touche LLPminorOthersFormer auditor replaced by RSM US LLP in April 2026. No disagreements or adverse opinions were reported from Deloitte.

Scale indicators7 records

Recent moves5 records

Expansion highlights3 records

Direct peers

• Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered TCR therapies for solid tumors. Highly comparable to Instil Bio's prior solid tumor cell therapy focus; board director Gwendolyn Binder is former CTO of Adaptimmune.
• Iovance Biotherapeutics: Leading commercial-stage developer of tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Most relevant direct competitor in the solid tumor cell therapy space where Instil previously operated.
• Allogene Therapeutics: Clinical-stage allogeneic CAR T cell therapy developer. Comparable as a public, clinical-stage cell therapy company pursuing off-the-shelf oncology cell therapy approaches.
• Cellectis: Clinical-stage gene-edited allogeneic cell therapy company. Comparable in modality (engineered cell therapy), clinical stage, and oncology focus.

Emerging players

• Cabaletta Bio: Clinical-stage cell therapy company focused on CAR T therapies. Board director Gwendolyn Binder is President of Science and Technology at Cabaletta, creating a direct professional linkage to Instil's board.
• TCR2 Therapeutics: Clinical-stage T cell receptor therapy developer for solid tumors. Board director Neil Gibson serves on TCR2's board and CEO Bronson Crouch was an early investor, providing direct comparability.
• Shattuck Labs: Clinical-stage immunotherapy company developing fusion proteins for cancer and inflammatory diseases. Board director Neil Gibson sits on Shattuck's board; comparable in clinical-stage oncology focus.
• Chimeric Therapeutics: Clinical-stage cell therapy company focused on solid tumors. Board director George Matcham previously served on Chimeric's board; comparable in solid tumor cell therapy focus.
• iTeos Therapeutics: Clinical-stage immuno-oncology company developing next-generation immunotherapies. CEO Bronson Crouch was a key early investor, providing a comparable case of a biotech Crouch backed through value-inflection stages.

Broad incumbents

• Alnylam Pharmaceuticals: Established commercial-stage RNAi therapeutics company. Strategic advisor John Maraganore was Alnylam's founding CEO for nearly two decades; comparable as a publicly-traded biotech with platform-based therapeutic approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Customer concentration

• LinkedInlinkedin.com/company/instil-bio
• Xx.com/InstilBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instil Bio